⚡ Trading Cheat Sheet — COO

• Ticker: COO (Nasdaq)
• Today’s Move: +6% intraday; peak of +6.8% flagged by momentum scanners
• Q2 Revenue: $1.082B beat vs. ~$1.065B consensus; up 8% YoY (5% organic)
• Non-GAAP EPS: $1.21 vs. $1.107 est. — up 26% YoY; 10th consecutive beat
• GAAP EPS: $(0.40) — distorted by $271.6M litigation charge (excluded from non-GAAP)
• The Legal Charge: $324.1M accrued settlement from Dec. 2023 embryo culture media recall at CooperSurgical; offset by $52.5M insurance recovery; 95%+ of claimants settled
• CooperVision (CVI): $723.5M revenue, +8% reported (+4% organic); toric/multifocal lenses +11%
• CooperSurgical (CSI): $358.0M revenue, +8% reported (+6% organic); fertility +13%
• FY2026 Guidance: Revenue $4.285B–$4.321B; Non-GAAP EPS $4.58–$4.66
• Free Cash Flow: $96.4M in Q2; LT target reaffirmed at $2.2B+ through FY2028
• Watch: Asia Pacific CVI organic revenue down 6%; new regional leadership in place; stabilization guided for Q4
• Tariff exposure: $22M baked into guidance; potential $15M refund upside if policy allows

COO: When the Ugly Number Is the Point

At first glance, $(0.40) diluted EPS looks like a company having a rough quarter. And that’s exactly why this setup worked.

The GAAP number is almost entirely one thing: a $271.6 million net pre-tax charge tied to settlements on a recall that happened in December 2023 at CooperSurgical. Embryo culture media. Resolved. More than 95% of claimants covered. Partially backstopped by $52.5M in insurance recovery. This isn’t a business problem disguised as a legal problem — it’s a concluded liability being booked and closed. That distinction matters more than most quick reads give it credit for, and the tape this morning knew it before most commentary caught up.

Ten consecutive non-GAAP beats. That’s the number underneath the noise.

What’s interesting is how broad the Q2 beat actually was. CooperVision didn’t grind out $723.5M on volume discounts. The growth was weighted toward toric and multifocal lenses — specialty, higher-margin product — up 11% on the reported line. Americas and EMEA are both running above 6% organic. CooperSurgical printed $358M, and the fertility segment inside that came in at 13% reported, 10% organic. IVF-adjacent demand has a different demand profile than most healthcare hardware — it doesn’t move with rate cycles the way capital equipment does, it moves with demographics and access, and both of those tailwinds are still building. That fertility number is not getting enough attention in the early reads today.

Worth a quick detour: management flagged that AI-driven inventory optimization prompted a deliberate production trim at CooperVision this quarter. That’s going to show up as a margin headwind in Q3 and some people will call it out negatively. I’d read it differently. Getting ahead of inventory before demand wobbles is what separates companies that manage through cycles from ones that blow up on impairment charges after the fact. Short-term friction, longer-term signal.

Here’s where my confidence gets softer.

Asia Pacific is a real problem, not a narrative one. CVI revenue dropped 6% organically across Japan, China, and Korea. New leadership is in place. Management is guiding for sequential stabilization by Q4, and that may happen — but APAC recoveries in med-tech tend to lag the Western comps by a full cycle, and the pricing dynamic in China specifically is brutal right now with domestic competition. It’s not a thesis-breaker, but anyone sizing this position should understand that APAC is a drag that doesn’t resolve quickly just because guidance says Q4. These things slip.

FY2026 guidance landed at $4.285B–$4.321B on revenue. Non-GAAP EPS range of $4.58–$4.66. Free cash flow came in at $96.4M for the quarter with the long-term $2.2B+ FCF target through FY2028 held intact. On tariffs: $22M is already in the model, and there’s a $15M potential refund sitting as upside that hasn’t been priced in.

The broader read from today’s session is less about COO specifically and more about how institutional money is handling legacy litigation exposure across healthcare hardware right now. Once a settlement structure becomes legible — once the insurance math is confirmed and the claimant population is fixed — buyers don’t wait for the next clean quarter to get in. They move on the clarity itself. That’s what today was. Whether it continues into next week or stalls as the CooperVision guidance tightening gets chewed on more carefully is the open question.

The demand is real. The legal chapter is effectively over. What happens to the stock from here depends on whether the next two quarters of execution can carry a multiple that’s now pricing in most of the good news.

Still worth watching closely.

— Editorial Desk